• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

    8.550 +0.080 (+0.94%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Amicus Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Stock Sees Improved Relative Strength Rating
    In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
    Via Investor's Business Daily
    The Analyst Landscape: 4 Takes On Amicus Therapeutics
     
    Via Benzinga
    Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
    - Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - 
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Time to buy these 3 healthcare companies that raised revenue guidance?
    The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
    Via MarketBeat
    Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
    These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. 
    Via InvestorPlace
    Topics Bankruptcy
    Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
    U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
    Via Benzinga
    Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
    The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease. 
    Via Benzinga
    Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
    Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
    Via Investor's Business Daily
    Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
    On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
    Via Investor's Business Daily
    Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
    On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
    Via Investor's Business Daily
    Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
    Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) 
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.